What is the optimal chemotherapy and immunotherapy regimen for a patient with a 2 cm recurrent tongue carcinoma documented on PET?

Optimal Chemoimmunotherapy for Recurrent Tongue Carcinoma

For a 2 cm recurrent tongue carcinoma, the ideal first-line regimen is pembrolizumab combined with platinum (cisplatin or carboplatin) plus 5-fluorouracil (5-FU) if the tumor expresses PD-L1 (CPS ≥1), or platinum/5-FU/cetuximab if PD-L1 is negative or immunotherapy is contraindicated. 1

Treatment Algorithm Based on PD-L1 Status and Prior Therapy

Step 1: Assess Resectability and PD-L1 Status

• First, determine if salvage surgery or re-irradiation is feasible - recurrent oral cavity lesions should be evaluated by a multidisciplinary team at a tertiary center for potential curative resection 1
• If unresectable or patient declines surgery, proceed to systemic therapy
• Obtain PD-L1 testing using FDA-approved immunohistochemistry - this is a validated biomarker that guides first-line therapy selection 1

Step 2: First-Line Systemic Therapy Selection

If PD-L1 CPS ≥1 (positive):

• Standard option: Pembrolizumab + platinum (cisplatin or carboplatin) + 5-FU 1

  • This combination improved overall survival to 13 months versus 10.7 months with platinum/5-FU/cetuximab
  • Level I evidence, Grade A recommendation
  • Use this regimen when rapid tumor shrinkage is needed 1

• Alternative option: Pembrolizumab monotherapy 1

  • Consider if patient is unfit for platinum-based chemotherapy
  • Lower toxicity profile but slower response
  • Level I evidence, Grade A recommendation

If PD-L1 negative (CPS <1) or immunotherapy contraindicated:

• Standard: Platinum (cisplatin or carboplatin) + 5-FU + cetuximab (EXTREME regimen) 1

  • Level I evidence, Grade A recommendation
  • ESMO-MCBS score: 3

• Alternative: TPeX (cisplatin/docetaxel/cetuximab) 1

  • Level II evidence, Grade B recommendation

Step 3: Important Pre-Treatment Considerations

Before initiating 5-FU:

• Perform DPD (dihydropyrimidine dehydrogenase) testing 1
  • DPD deficiency causes severe 5-FU toxicity
  • This is a mandatory recommendation

Cisplatin fitness assessment:

• If unfit for cisplatin (renal dysfunction, neuropathy, hearing loss), substitute with carboplatin 1

Key Clinical Nuances

Why Combination Over Monotherapy?

The KEYNOTE-048 trial established that pembrolizumab plus chemotherapy provides superior overall survival compared to chemotherapy alone (13 vs 10.7 months), with manageable toxicity 1. The combination is particularly important when rapid tumor control is needed for symptomatic disease or high tumor burden.

PD-L1 Testing is Critical

The efficacy of pembrolizumab is significantly higher in PD-L1-expressing tumors 1. However, the combination of pembrolizumab with chemotherapy shows benefit regardless of PD-L1 status, though the magnitude is greater in PD-L1-positive disease. For PD-L1-negative patients, the EXTREME regimen (platinum/5-FU/cetuximab) remains standard 1.

Common Pitfalls to Avoid

1. Don't delay systemic therapy for unresectable disease - if the 2 cm recurrence is not amenable to salvage surgery with acceptable functional outcomes, start systemic therapy promptly 1

2. Don't use immunotherapy monotherapy in PD-L1-negative disease - there is no evidence supporting this approach; use platinum/5-FU/cetuximab instead 1

3. Don't forget to assess prior platinum exposure timing - if the patient received platinum-based therapy within the last 6 months and progressed, they may benefit from immediate immunotherapy (nivolumab or pembrolizumab) rather than re-challenging with platinum 1

4. Don't overlook the need for multidisciplinary evaluation - even with a PET-documented 2 cm lesion, surgical salvage may offer better outcomes than systemic therapy alone in selected cases 1

Second-Line Therapy Considerations

If progression occurs within 6 months of platinum therapy:

• Nivolumab or pembrolizumab monotherapy 1
  • Level I evidence, Grade A recommendation
  • FDA and EMA approved
  • ESMO-MCBS score: 4

If immunotherapy contraindicated after platinum failure:

• Taxanes (docetaxel or paclitaxel) with or without cetuximab 1
• Methotrexate 1
• Level III evidence, Grade C recommendation

Strength of Evidence

The recommendations are based primarily on 2020 EHNS-ESMO-ESTRO guidelines published in Annals of Oncology [1-1], which represent the most comprehensive and recent consensus for oral cavity squamous cell carcinoma management. The KEYNOTE-048 trial data forms the backbone of the immunotherapy recommendations, with Level I evidence and Grade A strength across multiple guideline iterations.

The 2023 ASCO guideline 2 provides additional support for PD-1 inhibitor combinations, though it focuses more on nasopharyngeal carcinoma, which has different biology than oral tongue cancer.